Scientists have made a discovery that may help women at high risk of developing breast cancer.
These women have a mutation in a breast cancer gene. You may remember in 2013, actress Angelina Jolie, who has the mutated gene, made headlines after undergoing a preventetitve double mastectomy.
Now, scientists say a drug already on the market shows promise for women with this gene.
According to the National Cancer Institute, 65 percent of women with a mutation in the breast cancer gene BRCA1 will develop the disease by age 70. That number is only 12 percent for women in the general U.S. population.
But, a new study suggests a drug could provide new hope for women at the higher risk.
Denosumab -- also known by its brand names Prolia and Xgeva is already on the market for osteoporosis. Researchers used the drug to target a molecule called rank that's linked to the growth of cancerous cells.
The study looked at breast tissue samples and mice with the BRCA1 mutation and scientists discovered doses of Denosumab showed promise in blocking the molecule assocatated with the development of cancerous growths.
Researchers say this is merely a first step..and that results from a large clinical study would take up to 10 years.
However, Geoff Lindeman, a co-author of the study says, "This does offer hope for the next generation of women."